Key Highlights

  • Prime Medicine (NASDAQ:PRME) traded at USD 4.22 intraday on November 13, 2026, up 8.49%, giving a Market Value of about USD 766 million.
  • Third quarter Revenue rose to about USD 4.2 million from about USD 1.2 million, and the net loss narrowed to USD 39.0 million, or USD 0.22 a share, from USD 50.6 million, or USD 0.32.
  • A public offering priced at USD 3.50 a share closed in November with gross proceeds of about USD 143.7 million, and the company now expects cash to fund operations through 2027.
  • Initial clinical data for programmes in Wilson disease and alpha-1 antitrypsin deficiency are expected in 2027, and a filing for approval in chronic granulomatous disease is planned for the first half of 2027.

Results and Funding Remove a Near-Term Overhang

Prime Medicine's latest news is a combination of third quarter results on November 12, 2026 and the close of a share offering. The quarter was better than expected: revenue, mostly from collaborations, rose to about USD 4.2 million, and the net loss narrowed to USD 39.0 million, or USD 0.22 a share, as research spending was kept in check. More important for the stock is funding. On November 10 the company priced about 35.7 million shares at USD 3.50, and with the underwriters' option exercised in full, gross proceeds reached about USD 143.7 million and net proceeds about USD 134.7 million. Cash, investments and restricted cash were USD 74.8 million at September 30, and pro forma for the offering the figure is about USD 209.5 million. The company says that is enough to fund operations through 2027. The offering was priced well below the pre-deal price, which pushed the shares down, but the stock has since recovered to USD 4.22, above the offering price, suggesting investors welcome the removal of financing risk.

What Prime Editing Is and Where the Pipeline Stands

Prime Medicine, based in Cambridge, Massachusetts, develops therapies using prime editing, a gene editing technique designed to correct disease-causing mutations precisely without cutting both strands of DNA. Its pipeline has moved forward in recent months. The first patient was dosed in October in a trial of PM577a for Wilson disease, a rare disorder that causes copper to build up in the liver and brain, with initial data expected in 2027. The Food and Drug Administration cleared an investigational new drug application in September for PM647 in alpha-1 antitrypsin deficiency, with initial data also expected in 2027. For PM359 in chronic granulomatous disease, an immune disorder, the company plans to submit a Biologics license application in the first half of 2027. It also has a collaboration on ex vivo cell therapies with a large pharmaceutical partner and an in vivo cystic fibrosis programme.

Risks to Weigh

Prime Medicine (NASDAQ:PRME) is still a clinical stage company with no product revenue, and the offering added more than 41 million shares, which dilutes existing holders. Cash fell from USD 191.4 million at the end of 2025 to USD 74.8 million at September 30, a pace of spending that will continue as trials advance. The 2027 data readouts will be the decisive tests, and early gene editing data can disappoint. The company is also presenting at an investor conference on November 16, which may bring more detail on timelines.

Where Things Stand

Prime Medicine rose 8.49% to USD 4.22 on November 13, 2026 after better than expected third quarter results and an offering that extends its cash runway through 2027. The next catalysts are clinical data in 2027 and a planned approval filing for PM359. Dilution and trial outcomes remain the main risks.